Trials / Terminated
TerminatedNCT04729608
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
A Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB-S6-500) in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 366 (actual)
- Sponsor
- Aravive, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination with PAC in patients with platinum resistant recurrent ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Batiraxcept | Batiraxcept is an experimental drug |
| DRUG | Paclitaxel | Paclitaxel is the standard of care, background therapy |
| OTHER | Placebo | Matching placebo |
Timeline
- Start date
- 2021-04-22
- Primary completion
- 2023-08-04
- Completion
- 2023-08-04
- First posted
- 2021-01-28
- Last updated
- 2023-10-30
Locations
150 sites across 11 countries: United States, Belgium, Canada, China, Czechia, France, Georgia, Italy, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04729608. Inclusion in this directory is not an endorsement.